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Abstract
The introduction of highly active antiretroviral therapy has led to a significant reduction in the morbidity and mortality of
acquired immunodeficiency syndrome patients. However, the emergence of drug resistance has resulted in the failure of
treatments in large numbers of patients and thus necessitates the development of new classes of anti-HIV drugs. In this
study, more than 200 plant-derived small-molecule compounds were evaluated in a cell-based HIV-1 antiviral screen,
resulting in the identification of a novel HIV-1 inhibitor (fangchinoline). Fangchinoline, a bisbenzylisoquinoline alkaloid
isolated from Radix Stephaniae tetrandrae, exhibited antiviral activity against HIV-1 laboratory strains NL4-3, LAI and BaL in
MT-4 and PM1 cells with a 50% effective concentration ranging from 0.8 to 1.7 mM. Mechanism-of-action studies showed
that fangchinoline did not exhibit measurable antiviral activity in TZM-b1 cells but did inhibit the production of infectious
virions in HIV-1 cDNA transfected 293T cells, which suggests that the compound targets a late event in infection cycle.
Furthermore, the antiviral effect of fangchinoline seems to be HIV-1 enve1ope-dependent, as the production of infectious
HIV-1 particles packaged with a heterologous envelope, the vesicular stomatitis virus G glycoprotein, was unaffected by
fangchinoline. Western blot analysis of HIV envelope proteins expressed in transfected 293T cells and in isolated virions
showed that fangchinoline inhibited HIV-1 gp160 processing, resulting in reduced envelope glycoprotein incorporation into
nascent virions. Collectively, our results demonstrate that fangchinoline inhibits HIV-1 replication by interfering with gp160
proteolytic processing. Fangchinoline may serve as a starting point for developing a new HIV-1 therapeutic approach.
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Introduction
The global epidemic of acquired immunodeficiency syndrome
(AIDS) remains one of the most pressing public health emergen-
cies. According to the latest statistics provided by the Joint United
Nations Programme on HIV/AIDS (UNAIDS), there were an
estimated 33.3 million people living with HIV and 1.8 million
deaths due to AIDS in 2009. Since the emergence of HIV,
intensive studies have been undertaken to understand the disease
and find effective therapies. Currently, highly active antiretroviral
therapy (HAART) is considered to be the standard therapy
formula and has been proven to be successful in controlling viral
replication and disease progression. However, prolonged treat-
ment with combination regimens can be difficult to sustain
because of problems with adherence and toxic effects [1,2].
Furthermore, in a significant portion of treatment-experienced
patients, therapeutic options are limited due to the emergence of
drug resistance [3]. Moreover, cross-resistance between drugs
within a class frequently occurs [4]. Theoretically, the discovery
and development of drugs targeting alternative mechanisms in the
HIV-1 replication cycle should be the most effective strategy to
overcome drug resistance.
The HIV-1 envelope (Env) glycoproteins play an essential role
in the viral replication cycle by mediating attachment and fusion of
the viral envelope with the host cell membrane [5]. The Env
glycoproteins are synthesized as an inactive polyprotein precursor
(gp160) on the rough endoplasmic reticulum (RER) and targeted
to the endoplasmic reticulum (ER) by its N-terminal signal
peptide. Concomitant with translation, the signal peptide is
removed, and gp160 is subjected to extensive glycosylation.
Monomers of gp160 assemble into trimers and traffic into the
Golgi through the constitutive secretory pathway. In the Golgi,
gp160 is proteolytically cleaved by cellular furin or furin-like
proteases at a highly conserved motif to yield the surface subunit
gp120 and the transmembrane subunit gp41 [6]. Following
cleavage, gp120 and gp41 remain associated by noncovalent
interactions. Thereafter, the gp120/gp41 trimeric complex is
transported to the plasma membrane where it is incorporated into
the envelope of assembling HIV-1 particles.
Because the proteolytic cleavage of the viral envelope glyco-
protein is essential for the production of infectious virions [7],
gp160 processing might be an attractive target for anti-HIV-1
intervention [8]. Peptide or small-molecule inhibitors targeting the
expression of a functional HIV-1 Env have been previously
reported. Peptides derived from the cleavage region of gp160 have
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HIV-1 infection [9,10,11,12,13]. However, development of such
molecules for clinical application will face the challenges associated
with developing drugs from peptide-based compounds [14].
Furthermore, because a large number of host proproteins require
the host proprotein convertases for maturation and because all
proprotein convertases share the consensus (R/K)-X-R cleavage
sequence [15], these peptide substrate-competitive inhibitors may
also inhibit the cleavage of other host protein substrates in the
same manner. Small-molecule compounds that disrupt intracellu-
lar trafficking or glycosylation can also consequently inhibit gp160
cleavage into its active forms [6,16,17,18]. However, the clinical
potential of this class of compounds is limited due to the cell
toxicity caused by interfering with constitutive cellular functions.
More recently, a small-molecule compound that interferes with
gp160 processing resulting in the inhibition infectious-virion
production has been described [19]. However, this compound
exhibits a poor spectrum of activity against HIV-1 laboratory
strains, and its antiviral mechanism requires further elucidation.
Plants remain an important source of new drugs, new leads and
new chemical entities. Many compounds of plant origin have been
identified that inhibit different stages in the replication cycle of
HIV [20], and some of such compounds are currently in clinical
trials [20,21]. Therefore, plant-derived compounds may serve as
starting point for the development of anti-HIV drugs. In the
present study, we describe that a plant-derived small-molecule
compound, fangchinoline (6, 69, 12-trimethoxy-2, 29-dimethyl-
berbaman-7-ol), inhibits HIV-1 propagation by targeting Env at
a late stage of the viral replication cycle. Fangchinoline was
identified as a novel anti-HIV-1 agent by a cell-based screen of
compounds derived from Chinese herbal remedies. We show here
that fangchinoline inhibited HIV replication in MT-4 and PM1
cells but was not active in TZM-b1 cell assays. In a virus
production assay, fangchinoline reduced the production of in-
fectious virions in an Env-dependent manner. Further mechanism-
of-action studies demonstrated that fangchinoline specifically
interferes with gp160 processing and thus reduces the incorpora-
tion of Env into nascent viral particles.
Materials and Methods
Cell lines, plasmids and viruses
The human embryonic kidney cell line 293T was obtained from
American Type Culture Collection (ATCC). MT-4, C8166, PM1
and TZM-b1 cell lines were obtained through the NIH AIDS
Research and Reference Reagent Program. TZM-b1 cells and
293T cells were propagated in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10% FBS
(Gibco), 100 U/mL of penicillin and 0.1 mg/mL of streptomycin.
MT-4, PM1 and C8166 cells were grown in RPMI 1640
supplemented with 10% FBS and 10 mg/mL gentamicin. The
HIV-1 proviral clones pNL4-3 and pLAI.2, and the env-deficient
proviral clone pSG3Denv were obtained through the AIDS
Research and Reference Reagent Program. The vesicular
stomatitis virus glycoprotein (VSV-G) expressing plasmid
pVpack-VSV-G was purchased from Stratagene. The HIV-1
BaL Env expression plasmid, which was constructed by inserting
the Env sequence from HIV-1 BaL into pcDNA3.1, was provided
by Dr. Qinxue Hu (Wuhan Institute of Virology, Chinese
Academy of Sciences). The HIV-1 strains NL4-3 and LAI were
generated by transfecting 293T cells with the corresponding
plasmids and were propagated in MT-4 cells. The HIV-1 strain
BaL was obtained through the AIDS Research and Reference
Reagent Program.
Antibodies and compounds
Anti-VSV-G tag antibody (ab34774), anti-HIV-1 gp120
(ab21179) antibody and anti-HIV-1 p24 antibody (ab9071) were
purchased from Abcam. Anti-beta actin antibody (sc-130301) was
purchased from Santa Cruz. All horseradish peroxidase (HRP)–
labeled secondary antibodies were obtained from Thermo
Scientific.
The compounds isolated from Chinese traditional herbs for the
anti-HIV-1 drug screen were purchased from Sichuan Weikeqi
Biological Technology Co., Ltd., China. The purity of the
compounds was $98% by high-performance liquid chromatogra-
phy (HPLC) analysis. The compound samples were solved in
dimethyl sulfoxide (DMSO) at a concentration of 50 mM. The
following reference compounds were obtained through the NIH
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: indinavir sulfate (catalog no. 8145), zidovu-
dine (catalog no. 3485), integrase inhibitor 118-D-24 (catalog
no. 9957) and (-) flavopiridol (catalog no. 9925). Dextran sulfate
sodium salt (average molecule weight 5,000) was purchased from
Sigma-Aldrich.
In vitro anti-HIV-1 assays
The anti-HIV-1 activities of the compounds were evaluated
utilizing a variety of assays, including a cytopathic effect (CPE)
assay, p24 assay and TZM-b1 assay.
The CPE assay was performed in 96-well black-wall tissue
culture plates using MT-4 cells as targets. MT-4 cells were infected
with HIV-1 LAI or NL4-3 at a multiplicity of infection (MOI) of
0.1. To each well containing 1610
4 MT-4 cells, serial diluted test
compounds were added. Cell viability was measured 5 days post-
infection using the CellTiter-Glo reagent (Promega) according to
the manufacturer’s instructions. The luminescent signal was
determined using the Envision 2102 Multilabel Reader (Perkin
Elmer). The EC50 (50% effective concentration) values correspond
to compound concentrations that resulted in a 50% reduction in
cell death.
In p24 assays, MT-4 or PM1 cells were infected with HIV-1
LAI, NL4-3, or BaL at an MOI of 0.01. Infected cells were plated
in 96-well plates at a density of 1610
4 per well and serial diluted
test compounds were added. On day 4 post-infection, culture
supernatants were harvested and treated with Triton X-100. The
level of viral replication was determined by an HIV-1 capsid
protein (p24) antigen capture enzyme linked immunosorbent assay
(ELISA). Compound cytotoxicity was also determined in parallel
in mock-infected cells.
The TZB-b1 assay was utilized to determine the inhibitory
activity of fangchinoline against early and late events of the HIV-1
replication cycle. TZM-b1 cells contain the HIV primary receptor
CD4 and the coreceptors CCR5 and CXCR4, as well as a firefly
luciferase reporter gene driven by the HIV promoter. In this assay,
TZM-b1 cells were plated 1610
4 per well in 96-well tissue culture
plates one day before infection. On the day of the experiment, the
cell supernatant was removed, and serial diluted compounds in
volumes of 100 mL were added. HIV-1 NL4-3 in 100 mLo f
complete medium was then added to each well to achieve an MOI
of 1. At 48 hours post-infection, luciferase activity in the cells was
analyzed with the Steady-Glo reagent (Promega).
Semi-quantitative polymerase chain reaction (PCR)
analysis of intracellular HIV-1 viral DNA and mRNA
MT-4 cells were grown in 24-well plates and infected with NL4-
3 strain at a MOI of 0.02, and then test compounds were added to
desired concentrations. After incubating for 3 days, genomic DNA
Fangchinoline Inhibits HIV-1 Replication
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DNA Mini Preparation Kit (Beyotime, China) and TRIzol reagent
(Invitrogen Life Technologies), respectively. The Gag region,
representing total viral DNA, was amplified with previously
described primers [22]. A nested PCR was used for the
amplification of integrated proviral DNA, as previously described
with minor modification [23]. To determine viral mRNA
expression levels, 1 mg of RNA was treated with RQ1 RNase-
Free DNase (Promega) and reverse transcribed using M-MLV
Reverse Transcriptase (Promega) and random primers (Promega).
An aliquot of cDNA was used as a template for amplification of
the HIV-1 Gag region as described elsewhere [22]. As DNA and
RNA input controls, genomic DNA and cDNA was subjected to
GAPDH amplification using the primers 59-GAAGGT-
GAAGGTCGGAGTC-39 and 59-GAAGATGGTGATGG-
GATTTC-39. All of the PCR products were visualized on an
ultraviolet (UV) transilluminator in 2% agarose gels stained with
ethidium bromide. In preliminary experiments, the exponential
range of the PCR amplification curve was determined for all of the
PCR products by varying the amount of input DNA and the
number of PCR cycles. Based on these experiments, appropriate
conditions were chosen to perform semi-quantitative PCRs.
Virus production/infectivity assays
293T cells (90% confluent) grown in 24-well plates were
transfected with the HIV-1 infectious clone pNL4-3 or co-
transfected with env-deficient proviral clone pSG3
Denv and an
envelope expression plasmid, either HIV-1 BaL Env expression
plasmid or pVpack-VSV-G, using the FuGENE HD transfection
reagent (Roche). At 3 hours post-transfection, the cell supernatants
were removed and fresh medium with test compounds at the
indicated concentration were added. At 48 hours after trans-
fection, the virus release, virus infectivity and 293T cell viability
were examined. The supernatants of the transfected cells were
harvested for the evaluation of virus production and infectivity
determination. To evaluate the cytotoxicity of the test compounds
on 293T cells, the cells were resuspended in 500 mL of DMEM
medium, and 50 mL of the cell mixture was transferred to 96-well
plates to determine cell viability using the CellTiter-Glo reagent.
To detect virus release, one portion of culture supernatant was
treated with Triton X-100 and examined using the p24 ELISA.
The infectivity of the virus in the culture supernatants was also
determined utilizing the TZM-b1 assay. A total of 20 mLo f
supernatant in each well was transferred to 96-well plates
containing TZM-b1 cells in 180 mL of medium plated one day
before. The luminescence was determined 48 hours post-infection
using the Steady-Glo reagent.
Syncytium formation assays
MT-4 cells were infected with HIV-1 NL4-3 at a high MOI of
1. After incubating for 24 hours, the cells were washed and
incubated with 1 mM indinavir (IDV) alone or with 1 mM IDV
plus 2.5 mM fangchinoline for an additional 24 hours. Thereafter,
MT-4 cells were cultured with an equal number of the C8166 cells
in a culture plate in the presence of the same compounds in
duplicate. After 24 hours of cocultivation, syncytium formation
was examined using light microscopy.
Western blot analysis
293T cells were transfected with pNL4-3 as described above. At
3 hours post-transfection, the cell supernatant was removed and
fresh medium with a test compound was added. At 48 hours post-
transfection, the supernatants of the transfected cells were first
clarified by centrifugation for 5 min at 1,000 g at 4uC. Super-
natants were then layered on a 0.25-mL sucrose cushion (20%
sucrose/100 mM NaCl/10 mM Tris buffer, pH 7.5) and centri-
fuged at 4uC and 13,000 rpm (17,000 g) for 3 hours to pellet the
virions. After centrifugation, the supernatants were removed, and
the virus pellets were resuspended in 50 mL SDS polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer and boiled for
10 min. To prepare the cell-derived western blot samples, the
transfected cells were washed with phosphate buffered saline (PBS)
and lysed with radio immunoprecipitation assay (RIPA) lysis buffer
supplemented with complete mini protease inhibitor cocktail
(Roche) at 4uC for 1 hour. Proteins from concentrated virions and
cell lysates were separated by SDS-PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes. After overnight
incubation with primary antibodies at 4uC, each blot was probed
with horseradish peroxidase-conjugated secondary antibody.
Immunoreactive signals were detected with an enhanced chemi-
luminescence substrate (Thermo) using an AlphaEaseH FC
Imaging System (Alpha Innotech Corporation).
Pulse-chase analysis
Newly synthesized protein was labeled with Click-iT Metha-
bolic Labeling Reagents for Proteins (Invitrogen) according to
manufacturer’s instructions. 293T cells were transfected with
pNL4-3 as described above. At 3 hours post-transfection, the cell
supernatant was removed and fresh medium with or without
10 mM fangchinoline was added. After 24 hours, the cells were
labeled with 50 mM of AHA (Invitrogen) for 1 hour in methio-
nine-free medium with or without fangchinolie. The medium was
then changed with complete medium with or without fangchinolie,
and the cells were chased for indicated time. The cells were lysed
in the lysis buffer [(50 mM Tris HCl pH 8.0, 1%SDS, and
protease inhibitor (Roche)]. AHA incorporated protein was
biotinylated using Click-iT Protein Reaction Buffer Kit (Invitro-
gen) and Biotin Alkyne (Invitrogen). After precipitation and
dissolving, biotinylated protein was collected with Dynabeads
MyOne Streptavidin T1 (Invitrogen). The purified nascent protein
was eluted into SDS-PAGE sample buffer by boiling and
examined by Western blot analysis as described above.
Results
Screen of compounds derived from Chinese herbal
remedies led to the identification of fangchinoline as
a novel anti-HIV-1 agent
To identify novel anti-HIV agents, a set of more than 200
compounds isolated from traditional Chinese medicinal herbs was
screened utilizing an MT-4 cell CPE assay. In this HIV multiple-
cycle replication assay, the activity of the compounds against HIV-
1 replication was determined based on the inhibition of virus-
induced cytopathogenicity in MT-4 cells. Thus, compounds
having anti-HIV activities at any stage of the viral replication
cycle can be detected by this assay. Although the model does not
allow for high throughput screening, it incorporates all of the HIV-
1 targets required for replication and provides an opportunity to
identify compounds with novel anti-HIV-1 mechanisms.
All the compounds were tested over a wide range of
concentrations using 7 rounds of 3-fold serial dilutions starting at
30 mM. The anti-HIV activity of each compound was presented as
the maximum inhibition of virus-induced CPE at various
concentrations. Among all the tested compounds, fangchinoline,
a bisbenzylisoquinoline alkaloid isolated from Radix Stephaniae
tetrandrae, showed the most potent antiviral activity against HIV-1
strain LAI (Fig. 1). At the concentration 1.1 mM, fangchinoline
completely inhibited the CPE induced by HIV-1 replication.
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To confirm the anti-HIV-1 activity of fangchinoline in MT-4
cells, p24 assays were performed. NL4-3 infected MT-4 cells were
cultured in the presence of various concentrations of fangchino-
line, and p24 antigen production was determined by ELISA. To
exclude the possibility that the inhibitory effect was due to
nonspecific cytotoxicity, cell viability assays were performed in
parallel. As shown in Fig. 2B, fangchinoline inhibited p24 antigen
expression in a dose-dependent manner at concentrations ranging
from 0.6 mM to 2.5 mM, which were below the toxicity threshold
(5 mM) for the host cells. At 2.5 mM, fangchinoline reduced p24
antigen expression by 97.2% without obvious toxicity (Fig. 2A and
2B), suggesting the compound specifically inhibited viral replica-
tion without alteration of the host metabolism.
To further characterize the effect of fangchinoline on HIV-1
replication, viral DNA and mRNA synthesis were determined by
semi-quantitative PCR assays. Total DNA and RNA of NL4-3
infected MT-4 cells were extracted and total viral DNA, integrated
proviral DNA and viral mRNA were amplified as described in the
Materials and Methods. Consistent with the observations in p24
assays, at non-toxic concentrations (0.6–2.5 mM) fangchinoline
inhibited total viral DNA, integrated proviral DNA and viral
mRNA synthesis in a dose-dependent manner (Fig. 2C and 2D).
All these results confirmed the antiviral activity of fangchinoline
against HIV-1 NL4-3 in MT-4 cells.
We next determined whether the anti-HIV activity of
fangchinoline was specific to the cell type or viral strain. Antiviral
Figure 1. Screen of compounds derived from Chinese herbal
remedies led to the identification of fangchinoline as a novel
anti-HIV-1 agent. (A) MT-4 cells were infected with HIV-1 LAI at an
MOI of 0.1 or mock infected in the presence of serially diluted test
compounds. Cell viability was measured 5 days post-infection. The anti-
HIV activity of each compound was presented as the maximum
inhibition of CPE at various concentrations. (B) The chemical structure of
fangchinoline.
doi:10.1371/journal.pone.0039225.g001
Figure 2. Fangchinoline inhibits HIV-1 NL4-3 replication in MT-
4 cells. (A and B) MT-4 cells were infected with HIV-1 NL4-3 at an MOI
of 0.02 or mock infected in the presence of serially diluted fangchino-
line. On day 4 post-infection, compound cytotoxicity was determined in
parallel in mock-infected cells (A), and the level of viral replication in
infected cells was determined by p24 antigen capture ELISA (B). The
results were presented as the mean values with standard deviations. (C
and D) MT-4 cells were infected with HIV-1 NL4-3 at an MOI of 0.02 in
Fangchinoline Inhibits HIV-1 Replication
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host cells was determined in p24 assays. As shown in Table 1,
fangchinoline exhibited comparable potency against T-tropic
strains (NL4-3, LAI) and an M-tropic strain (BaL) with EC50
values ranging from 0.8 to 1.7 mM and selective indexes (SIs) from
3.8 to 8.6. Thus, fangchinoline showed relatively weak but
substantial antiviral activity against different HIV-1 strains in T
cell lines.
Fangchinoline does not act at early stages of the HIV-1
replication cycle
To determine the stage of the replication cycle targeted by
fangchinoline, a TZM-b1 assay was performed. TZM-b1 cells are
permissive to HIV-1 infection and harbor an integrated copy of
the luciferase gene under transcriptional control of the HIV long-
terminal repeat sequence [24]. Reporter gene expression is
induced by viral Tat protein after infection. This assay monitors
the early steps of infection up to the integration of the viral cDNA
into the host cell chromosome and expression of the viral gene Tat
[25]. Fangchinoline along with a panel of reference compounds
with known anti-retroviral mechanisms were evaluated in this
assay. For comparison, the anti-HIV-1 activities of these
compounds in MT-4 CPE assays were also determined.
As shown in Table 2, the compounds acting at the early stages
of the replication cycle, including dextran sulfate (entry inhibitor),
zidovudine (AZT, reverse-transcriptase inhibitor), integrase in-
hibitor 118-D-24 (INI 118-D-24) and flavopiridol (gene expression
inhibitor), caused significant reductions in luciferase gene expres-
sion with comparable potency as determined in MT-4 CPE assays.
However, the protease inhibitor indinavir (IDV), which acts at
a late stage after gene expression, did not show inhibitory effects at
concentration as high as 5 mM. As observed in the case of
indinavir, fangchinoline did not exhibit measurable antiviral
activity up to concentrations that were cytotoxic to the host cells,
indicating that fangchinoline blocks viral replication at a stage
after viral DNA integration and gene expression.
Fangchinoline inhibits the production of infectious HIV-1
particles
To confirm fangchinoline targets a late event in the HIV-1
replication cycle, the effect of fangchinoline on infectious HIV-1
particle production was examined in the virus production/
infectivity assay. Infectious virus was produced by transfecting
293T cells with infectious HIV-1 viral cDNA pNL4-3 in the
presence or absence of compounds, and the infectivity of the
nascent virus was tested utilizing TZM-b1 indicator cells.
Although cytotoxicity to MT-4 cells was observed as concentra-
tions exceeded 5 mM, fangchinoline didn’t obviously affect the cell
viability of 293T cells at 10 mM (Fig. 3A). AZT and IDV were also
tested in the assay as early stage and late stage inhibitor controls.
As expected, AZT was not active in this assay, while IDV
completely inhibited the infectious virus production at the test
concentration (Fig. 3A). Of note, fangchinoline dose-dependently
inhibited the production of infectious virus with an EC50 value of
approximate 2.5 mM (Fig. 3B). In contrast, fangchinoline treat-
ment did not affect HIV-1 particle production as the extracellular
viral capsid protein levels were comparable with the untreated
control (Fig. 3B), which indicates that fangchinoline does reduce
the infectivity of nascent particles at a late step of the replication
cycle.
Because it was reported that protease inhibitors and maturation
inhibitors, which inhibit Gag proteolytic processing, can reduce
the infectivity of nascent viruses [26,27], we further tested whether
fangchinoline acts by a similar mechanism. Gag protein products
derived from virions produced from pNL4-3 transfected 293T cells
in the presence of the test compounds were examined by Western
blot analysis, as described in the Materials and Methods. As
a positive control, IDV was shown to inhibit the viral protease
resulting in the detection of multiple uncleaved Gag precursor
proteins. In contrast, Gag processing was not affected in virions
produced in the presence of the negative control AZT or
fangchinoline (Fig. 3C). These results demonstrated that fangchi-
noline does not reduce virus infectivity by interfering with HIV-1
virion maturation.
Fangchinoline specifically reduces the incorporation of
HIV-1 Env into nascent virus particles
Because the decreased infectivity of HIV-1 particles produced in
the presence of fangchinoline could be due to the reduced ability
of the virus to enter target cells and because Env plays an essential
role in the initiation of infection, we next tested whether
fangchinoline inhibits the production of infectious virions in an
Env-dependent manner. HIV Gag particles packaged with HIV-1
Env (BaL) or with heterologous envelope (vesicular stomatitis virus
G glycoprotein, VSV-G) were prepared by transient transfection
in 293T cells and titrated in TZM-b1 indicator cells. As shown in
Fig. 4A, the presence of fangchinoline remarkably reduced the
infectivity of the particles pseudotyped with wild-type HIV-1 Env.
However, fangchinoline treatment did not significantly alter the
infectivity of the virus particles packaged with the VSV-G
envelope. Unsurprisingly, protease inhibitor IDV was active
against both pseudoviruses as it targets Gag particle maturation,
which was required by both psuedoviruses (Fig. 4A). These results
strongly suggested that fangchinoline specifically targets HIV-1
Env late in viral replication cycle.
At a late stage of HIV-1 replication cycle, Env is trafficked to
the cellular surface for incorporation into the assembling virus
particles. To determine if fangchinoline affects the incorporation
of HIV-1 Env proteins into virions, we next examined the content
of Env in the HIV-1 particles produced by 293T cells in the
the presence of test compounds (AZT, 0.05 mM; fangchinoline, 0.3–
2.5 mM), and genomic DNA and mRNA from infected cells were isolated
3 days post-infection. Total viral DNA (C, upper panel), integrated
proviral DNA (C, middle panel) were examined by semi-quantitative PCR
analysis. Viral mRNA levels were examined by semi-quantitative reverse
transcription PCR analysis (D, upper panel). GAPDH was used as both
the DNA and RNA input control.
doi:10.1371/journal.pone.0039225.g002
Table 1. In vitro antiviral activities of fangchinoline against
different HIV-1 laboratory strains.




HIV-1 NL4-3 MT-4 0.8 6.9 8.6
HIV-1 NL4-3 PM1 1.5 6.4 4.3
HIV-1 LAI MT-4 1.3 6.9 5.3
HIV-1 BaL PM1 1.7 6.4 3.8
Antiviral assays were performed as described in Materials and Methods. Values
represent average of at least three independent experiments.
aCompound concentration required to reduce the production of p24 antigen by
50%.
bCompound concentration required to reduce mock-infected cell viability by
50%.
cSelective index, ratio of CC50/EC50.
doi:10.1371/journal.pone.0039225.t001
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Fig. 4B, the incorporation gp120 was reduced by fangchinoline in
a concentration-dependent manner, whereas the incorporation of
gp160 and the p24 levels remained unaffected. In the presence of
10 mM fangchinoline, the incorporation of gp120 was substantially
abolished, which is consistent with the observation in the virus
production/infectivity assay in which the production of infectious
viral particles was reduced by 95.3% (Fig. 3B). On the contrary,
the incorporation of VSV-G into pseudotyped HIV-1 particles was
not affected by fangchinoline at 1.3–10 mM (Fig. 4C). These data
showed that fangchinoline directly or indirectly reduces Env
incorporation into HIV-1 particles.
Fangchinoline reduces functional Env expression by
interfering with gp160 processing
Although the actual mechanism of Env incorporation still
remains a matter of controversy, all the current postulated models
suggest that functional Env presentation on the surface of
producer cells is essential [5]. Thus, we next investigated the
effect of fangchinoline on the expression of functional Env on the
cell surface using a syncytium formation assay. In the assay,
functional Env expression on the surface of effector cells induces
cell-cell fusion between cocultured cells. NL4-3 infected MT-4
cells were either untreated or treated with 2.5 mM fangchinoline
for 24 hours. In addition, 1 mM IDV was added to prevent the
production of infectious virions. Then, the cells were cocultured
with C8166 cells, which are sensitive to Env-induced syncytium
formation. As shown in Fig. 5A, IDV alone did not inhibit the
formation of large multinuclear cells. In contrast, in the presence
of fangchinoline, giant multinuclear cells were rarely observed.
Considering fangchinoline is not active at the early stages of the
viral replication cycle, we conclude that fangchinoline treatment
reduces the functional Env expression on the surface of infected
MT-4 cells.
Because the proteolytic processing of gp160 is absolutely
required for activation of the fusogenic activity of Env, we next
examined the effect of fangchinoline on gp160 processing. Env
protein expression in cells transfected with the HIV-1 NL4-3
cDNA was analyzed by Western blot analysis using a polyclonal
antibody directed against HIV-1 gp120. As shown in Fig. 5B, two
distinct proteins (gp120 and gp160) were detected in the samples
(upper panel). As the concentration of fangchinoline increased, the
band intensity of gp120 decreased indicating a concentration-
dependent inhibition of gp160 processing, which correlated with
the inhibition of infectious virus production. As gp160 was
a predominant protein detected in transfected cells (Fig. 5B, lane
1), we did not observe any obvious accumulation of uncleaved
gp160 in fangchinoline treated cells (Fig. 5B, lane 2–4). To confirm
that fangchinoline inhibits gp160 process, pulse–chase analysis was
carried out to study the kinetics of gp160 processing in cells.
pNL4-3 transfected 293T cells were labeled 1 hour and chased for
0, 2, 4, and 8 hours in the presence or absence of 10 mM
fangchinoline. The results showed that newly synthesized gp160
was present in untreated cells and gradually decreased during the
chase period. However, in the presence of fangchinoline, gp160
content remained unchanged up to 8 hours (Fig. 5C). Since the
gp120 product was not observed under our experimental
conditions, the decrease of the labeled gp160 could be a result
of processing into gp120/gp41, incorporation into virus particles
or degradation. However, as shown in Fig. 4B, the incorporation
of gp160 into virus particles was not significantly affected by
fangchinoline. Furthermore, the Western blots of whole cell lysates
indicated that fangchinoline did not obviously alter the degrada-
tion of gp160 (Fig. 5B). Taken together, these results suggested that
fangchinoline inhibits gp160 processing, rather than degradation
or incorporation into virus particles.
Discussion
Because target-based approaches are limited to developing
novel treatments for validated targets, it is important to screen for
inhibitors of novel targets in the context of a full viral replication
cycle. In the present study, we screened more than 200
compounds, which were isolated from traditional Chinese
medicinal herbs, using a full viral replication cycle assay resulting
in the identification of fangchinoline as a novel anti-HIV-1 agent
(Fig. 1). Our unpublished data showed that fangchinoline did not
show an inhibitory effect on virus-induced CPE in influenza virus-
infected MDCK cells or on HBV HBeAg or HBsAg expression in
HepG2.117 cells, which indicates that the antiviral activity of
fangchinoline may be specific to HIV-1. Although in vitro antiviral
data indicated that the SI values were relatively low, the antiviral
activity of fangchinoline was confirmed in a variety of assays and
cannot be attributed to unspecific cell pathogenic effects. Of note,
the further mode-of-action study showed that fangchinoline
inhibits HIV-1 replication by impairing gp160 processing,
a mechanism that has not been exploited by any commercially
available drug for HIV-1 treatment.
Fangchinoline was demonstrated to have anti-HIV activity in
full replication assays (Fig. 2 and Table 1) but not in the TZM-b1
assay (Table 2), indicating that it interferes with a process(es) after
proviral transcription in the viral replication cycle. In the virus
production/infectivity assay, fangchinoline reduced the infectivity
of nascent virions and had no effect on viral release (Fig. 3A and
Table 2. Anti-HIV activities of test compounds in MT-4 CPE assays and TZM-b1 assays.
Compound EC50 in CPE assays
a EC50 in TZM-b1 assays
b Stage of action
Dextran sulfate 0.3 mg/mL 0.1 mg/mL Entry
AZT 5.7 nM 4.9 nM Reverse transcription
INI 118-D-24 13.6 mM 4.0 mM Integration
Flavopiridol 2.1 nM 2.6 nM Gene expression
IDV 5.3 nM .5.0 mM Maturation
Fangchinoline 0.7 mM .5.0 mM
Antiviral assays were performed as described in Materials and Methods. Values represent average of at least three independent experiments.
aCompound concentration required to reduce the virus-induced CPE by 50%.
bCompound concentration required to reduce the luciferase expression in virus infected TZM-b1 cells by 50%.
doi:10.1371/journal.pone.0039225.t002
Fangchinoline Inhibits HIV-1 Replication
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e392253B). After excluding the possibility that fangchinoline affects virion
maturation (Fig. 3C), we found that the anti-HIV-1 activity of
fangchinoline is Env dependent because the production of
infectious VSV-G protein packaged HIV-1 virus was not affected
Figure 3. Fangchinoline inhibits the production of infectious
HIV-1 particles. (A and B) 293T cells were transfected with the HIV-1
infectious clone pNL4-3. At 3 hours post-transfection, the cell
supernatant was removed, and fresh medium with test compounds
(AZT, 0.05 mM; IDV, 1 mM; fangchinoline, 0.6–10 mM) was added. At
48 hours after transfection, viral release, viral infectivity and the cell
viability of 293T were examined, as described in the Materials and
Methods. (C)The Gag protein products derived from virions produced
from pNL4-3 transfected 293T cells in the presence of test compounds
(AZT, 0.05 mM; IDV, 0.25 mM; fangchinoline, 1.3–10 mM) were examined
by Western blot analysis.
doi:10.1371/journal.pone.0039225.g003
Figure 4. Fangchinoline specifically reduces the incorporation
of HIV-1 Env into nascent virus particles. (A) 293T cells were co-
transfected with pSG3
DEnv and an envelope expressing plasmid. At
3 hours post-transfection, the cell supernatant was removed, and fresh
medium with test compounds (IDV, 1 mM; fangchinoline, 1.3–10 mM)
was added. At 48 hours after transfection, the infectivity of the virions
produced by the co-transfected cells was determined in the TZM-b1
assay. (B) 293T cells were transfected with pNL4-3. At 3 hours post-
transfection, the cell supernatant was removed, and fresh medium with
indicated concentration of fangchinoline was added. At 48 hours after
transfection, the content of Env in the HIV-1 particles produced by the
pNL4-3 transfected 293T cells was analyzed by Western blot. (C) 293T
cells were cotransfected with pSG3
Denv and pVpack-VSV-G. At 48 hours
after transfection, the content of VSV-G in the pseudotyped HIV-1
particles produced in the presence or absence of fangchinoline was
analyzed by Western blot.
doi:10.1371/journal.pone.0039225.g004
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line interferes with gp160 processing resulting in reduced cell-
surface expression of functional Env and decreased Env in-
corporation into nascent virus (Fig. 4B and Fig. 5).
As mentioned above, a relatively low therapeutic index exists for
fangchinline in the in vitro anti-HIV-1 assay, indicating the
therapeutic utility in its current form is very limited. However,
further structure-activity relationship study may help solve this
problem. Fangchinoline has many naturally occurring analogues
with a bisbenzylisoquinoline structure. Our unpublished data
demonstrated that tetrandrine, a close related analogue of
fangchinoline, exerted a similar anti-HIV-1 profile of fangchino-
line. These analogues may serve in the structure-activity relation-
ship study to uncover the scaffold responsible for the anti-HIV-1
activity of fangchinoline. Based on these data, chemical modifi-
cation introduced into this compound may yield new derivative
with reduced cytotoxicity and/or improved antiviral potency.
However, until now, we can not determine from the chemical
structure whether fangchinoline is a druggable compound, it is also
possible that the chemical nature makes the compound can not
move forward to further drug development.
Although all the results provide strong evidence that fangchino-
line interrupts gp160 processing, the exact mechanism responsible
for the observed inhibition of HIV production in fangchinoline
treated cells requires additional study. In theory, several action
mechanisms, either targeting host cells or the virus, can result in
similar observations. Based on previously published data, fangchi-
noline may target host proprotein convertases involved in gp160
processing and inhibit their endoproteolytic activity. Fangchino-
line was described to lower blood pressure as a non-specific Ca
2+
channel antagonist [28]. Moreover, previous studies showed that
Ca
2+ is required for the processing of gp160 as Ca
2+ depletion in
the cellular compartment leads to a reduction in cleavage
efficiency [29]. Thus, fangchinoline may impair the activity of
these related enzymes by decreasing the concentration of Ca
2+ in
cells. However, it appears that the inhibition of the associated host
Figure 5. Fangchinoline reduces functional Env expression by interfering with gp160 processing. (A) HIV-1 NL4-3-infected MT-4 cells
were pretreated with 1 mM IDV alone (left panel) or 1 mM IDV plus 2.5 mM fangchinoline (right panel) for 24 hours and then cocultured with C8166
cells. After 24 hours of cocultivation, syncytium formation was examined using light microscopy. (B) 293T cells were transfected with pNL4-3 and
treated with the indicated concentration of fangchinoline. The Env protein expression in transfected cells was analyzed by Western blot using
a polyclonal antibody directed against HIV-1 gp120 48 hours post-transfection. (C) 293T cells were transfected with pNL4-3. At 3 hours post-
transfection, the cell supernatant was removed and fresh medium with or without 10 mM fangchinoline was added. After 24 hours, the cells were
labeled for 1 h and chased for indicated times in the presence or absence of fangchinoline. After biotinylated, the newly synthesized protein was
collected with streptavidin-coupled magnetic beads. Processing of newly synthesized gp160 was examined by Western blot analysis.
doi:10.1371/journal.pone.0039225.g005
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did not exhibit activity against influenza viruses (data not shown).
Similar to HIV-1, proteolytic activation of influenza virus
hemagglutinin (HA) by host cell proteases is essential for viral
infectivity. HA cleavage is likely mediated by one or more
proprotein-processing subtilisin-related endoproteases of which
furin is the leading candidate [30]. If fangchinoline impairs
convertase activity by blocking Ca
2+ channel, it should be active
against both HIV-1 and influenza viruses. Thus, the anti-HIV-1
activity of fangchinoline may not be sufficiently explained by the
inhibition of endoproteolytic activity of related host proprotein
convertases. Of course, we cannot rule out the possibility that
fangchinoline indirectly inhibits gp160 processing by disrupting
oligosaccharide trimming or intracellular trafficking. As mentioned
above, intracellular trafficking is essential for gp160 maturation
and infectious virion production [6]. Megalomicin, a macrolide
antibiotic has been shown to inhibit vesicular transport between
medial-Golgi and trans-Golgi and consequently gp160 cleavage
into its active forms [16]. Moreover, post-translational modifica-
tions of gp160 play a crucial role in its intracellular trafficking.
Several compounds (castanospermine, deoxynojirmycin, and
monensin) that inhibit glycosylation trimming, and subsequent
gp160 trafficking and processing have been described [31,32,33].
However, such inhibitors target important host cell functions, thus,
their clinical potential is limited due to safety concerns. If
fangchinoline acts by any of these mechanisms mentioned above,
its potential for further drug development will be limited.
Alternatively, fangchinoline may specifically target HIV-1 Env
rather than host factors. In theory, fangchinoline may bind to
HIV-1 Env and alter the natural conformation of gp160 in such
a way that furin or other proprotein convertases are unable to
access the cleavage site. In this case, the weak anti-HIV-1 activity
should not be inherent in the profile of action, and fangchinoline
may be used as a starting point for developing new HIV-1
therapeutic approaches. Based on further structure-activity re-
lationship research, additional potent derivatives with lower
toxicity may be developed. The successful development of
Bevirimat (PA-457, DSB, MPC-4326) demonstrates the feasibility
of utilizing natural products as the starting point for the
development of new therapeutic approaches for HIV-1 infection
[34]. Bevirimat is a first-in-class maturation inhibitor, and its
development was based on a plant triterpene betulinic acid [35].
Although the original form of betulinic acid exhibited inhibitory
activity against HIV-1 replication in H9 lymphocyte cells with a SI
of only 9.3, its potent derivative 3-O-(30,30-dimethylsuccinyl)
betulinic acid is currently in clinical trials [21].
In summary, our results presented in this study demonstrate that
fangchinoline inhibits HIV-1 replication by interfering with gp160
proteolytic processing. Although the therapeutic utility in its
current form is limited, fangchinoline may serve as a starting point
for developing a new HIV-1 therapeutic approach or as a basic
research tool for interrogating events during HIV Env maturation.
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